Clinical Trials Browser

Completed × cediranib × Breast × Clear all

Advanced Breast Cancer

NCT00244881 2015-12-07

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Phase 2 Completed

26 enrolled 9 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

20 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

40 enrolled

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Clinical Trials

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours